Lapatinib, Di-p-Toluenesulfonate Salt (Lapatinib Ditosylate, Tykerb, GW-572016, Tyverb, CAS 388082-77-7), >99%

LC Laboratories' Product Number L-4804 - Lapatinib, Di-p-Toluenesulfonate Salt (Lapatinib Ditosylate, Tykerb, GW-572016, Tyverb), >99% - for research use only. Lapatinib inhibits both epidermal growth factor receptor (EGFR) and HER2/neu (ErbB-2) tyrosine kinases by binding to the intracellular phosphorylation domain, preventing receptor autophosphorylation. The exact site of binding has currently not been confirmed. It appears to arrest the development of breast cancer in some patients with metastatic, treatment-refractory disease. Potent inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM), ErbB-4 kinase (Ki = 347 nM). Lapatinib can restore tamoxifen sensitivity in tamoxifen-resistant, ER-positive breast cancer models. Lapatinib is the active ingredient in the drug sold under the trade name Tykerb® in the US and Tyverb in Europe. This drug has been approved in at least one country to treat advanced metastatic breast cancer in conjunction with the chemotherapy drug Xeloda (Cat. No. C-2799).

• Supplier: LC Laboratories
• Product #: L-4804
• Sku #: L-4804_200mg